Search Patents
  • Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines
    Patent number: 11384122
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: July 12, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel le Gars, Jerald C. Sadoff
  • Compositions and methods for preventing and treating coronavirus infection—SARS-CoV-2 vaccines
    Patent number: 11498944
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: January 30, 2021
    Date of Patent: November 15, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel Le Gars, Jerald C. Sadoff
  • MESSENGER RNA VACCINES AGAINST WIDE SPECTRUM OF CORONAVIRUS VARIANTS
    Publication number: 20240066113
    Abstract: The present invention relates to the mRNA vaccine of coronavirus spike protein with deletion of glycosites in the receptor binding domain (RBD), the subunit 1 (S1) domain, or the subunit 2 (S2) domain, or a combination thereof. The vaccine elicits broadly protective immune responses coronavirus and variants thereof.
    Type: Application
    Filed: April 12, 2022
    Publication date: February 29, 2024
    Inventors: Chi-Huey WONG, Chung-Yi WU, Che MA, Chen-Yu FAN
  • PAN-CORONAVIRUS VACCINE COMPOSITIONS
    Publication number: 20230226173
    Abstract: Pan-coronavirus recombinant vaccine compositions featuring whole proteins or sequences of proteins encompassing all mutations in variants of human and animal Coronaviruses (e.g., 36 mutations in spike protein) or a combination of mutated B cell epitopes, mutated combination of B cell epitopes, mutated CD4+ T cell epitopes, and mutated CD8+ T cell epitopes, at least one of which is derived from a non-spike protein. The mutated epitopes may comprise one or more mutations. The present invention also describes using several immuno-informatics and sequence alignment approaches to identify several human B cell, CD4+ and CD8+ T cell epitopes that are highly mutated. The vaccine compositions herein have the potential to provide long-lasting B and T cell immunity regardless of human and animal Coronaviruses mutations.
    Type: Application
    Filed: October 13, 2022
    Publication date: July 20, 2023
    Inventor: Lbachir BenMohamed
  • Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines
    Patent number: 5672350
    Abstract: Nucleic acid sequences encoding the Bovine Coronavirus E2 (or BCV S) and E3 (or BCV HE) structural glycoproteins and methods of producing these proteins, including recombinant expression, e.g., in mammalian or insect cells, are provided. The E2 and E3 proteins or antigenic fragments thereof are useful components for Bovine Coronavirus vaccines and methods of treatment.
    Type: Grant
    Filed: December 22, 1993
    Date of Patent: September 30, 1997
    Assignee: Veterinary Infectious Disease Organization
    Inventors: Michael D. Parker, Graham J. Cox, Lorne A. Babiuk
  • CORONAVIRUS RNA VACCINES
    Publication number: 20220323572
    Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: November 3, 2021
    Publication date: October 13, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Mihir Metkar, Valdimir Presnyak
  • Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
    Publication number: 20230075527
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: January 30, 2021
    Publication date: March 9, 2023
    Inventors: Dan H. BAROUCH, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, An VANDEBOSCH, Mathieu Claude Michel LE GARS, Jerald C. SADOFF
  • Compositions and Methods for Preventing and Treating Coronavirus Infection - SARS-COV-2 Vaccines
    Publication number: 20210246170
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: January 30, 2021
    Publication date: August 12, 2021
    Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
  • COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
    Publication number: 20210388032
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Application
    Filed: July 28, 2021
    Publication date: December 16, 2021
    Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Thedorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
  • CORONAVIRUS RNA VACCINES
    Publication number: 20210228707
    Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: August 21, 2020
    Publication date: July 29, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Mihir Metkar, Vladimir Presnyak, Guillaume Stewart-Jones
  • METHODS OF MAKING AND USING A VACCINE AGAINST CORONAVIRUS
    Publication number: 20230242940
    Abstract: Provided herein are vaccines against coronavirus that utilize adeno-associated virus (AAV) for delivery.
    Type: Application
    Filed: April 13, 2021
    Publication date: August 3, 2023
    Applicants: Massachusetts Eye and Ear Infirmary, The Schepens Eye Research Institute, Inc.
    Inventors: Luc H. Vandenberghe, Urja Achal Bhatt, Nerea Zabaleta Lasarte, Wenlong Dai
  • NOVEL CORONAVIRUS TANDEM EPITOPE POLYPEPTIDE VACCINE AND USE THEREOF
    Publication number: 20230338510
    Abstract: Provided are a tandem epitope polypeptide vaccine for novel coronavirus and use thereof. Specifically, a vaccine polypeptide for novel coronavirus pneumonia is provided on the basis of analysis and study of the RBD sequence and structural information of the S protein of SARS-CoV-2. Said vaccine polypeptide comprises the following elements connected in series: a generic Th epitope sequence, a B cell epitope sequence and a T cell epitope sequence. The B cell epitope and the T cell epitope have an amino acid sequence from the RBM region of the S protein of SARS-CoV-2. Provided are a vaccine composition containing said vaccine polypeptide and use thereof. Experiments show that the vaccine polypeptide of the present invention can enable cynomolgus monkeys to initiate strong cellular and humoral immunity, and to generate neutralizing antibodies that block the binding of RBD and ACE2, and can be used for preventing and treating novel coronavirus pneumonia.
    Type: Application
    Filed: June 11, 2021
    Publication date: October 26, 2023
    Inventors: Likun GONG, Jin REN, Qiuping QIN, Weiliang ZHU, Yiru LONG, Zhijian XU, Jianhua SUN, Tingting LIU, Guangyi JIN, Jianping ZUO, Wei HUANG
  • SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES
    Publication number: 20230233666
    Abstract: Disclosed are synthetic MVA-based vaccines for preventing or treating infections caused by a coronavirus or variants thereof.
    Type: Application
    Filed: September 14, 2022
    Publication date: July 27, 2023
    Inventors: Don J. DIAMOND, Felix WUSSOW, Flavia CHIUPPESI
  • Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
    Patent number: 5916570
    Abstract: New purified and isolated bovine coronavirus (BCV) types (II and III) are described which can be used to create new modified live vaccines for administration to cattle in order to confer immunity against virulent wild-type bovine coronavirus infection. Preferably, a multivalent modified live vaccine is provided for oral-nasal administration which includes the known Type I virus and the new Types II and III virus. Hygromycin B has also demonstrated to be effective for suppressing BCV replication and thus can be administered to cattle as a treatment for the chronic disease and to suppress shedding of BCV in cattle feces.
    Type: Grant
    Filed: February 4, 1997
    Date of Patent: June 29, 1999
    Assignee: Kansas State University Research Foundation
    Inventor: Sanjay Kapil
  • Method of Obtaining Betulin as an Adjuvant in a Vaccine Against Coronavirus SARS-COV-2
    Publication number: 20240115695
    Abstract: The invention relates to biotechnology, and specifically to a method for creating the adjuvant betulin, suitable for preparing a vaccine against coronavirus SARS-CoV-2. The method consists in sterilizing filtration of a solution of betulin in tetrahydrofuran through a nylon membrane with a pore diameter of 0.22 ?m, decreasing the tetrahydrofuran content by adding a 25-fold volume of sterile 0.01 M tris-buffer (pH 9.0+0.1), and subsequently homogenizing by ultrasound until a homogeneous suspension results, forming spherical amorphous homogeneous particles suitable for binding proteins of the SARS-CoV-2 virus. The proposed technique makes it possible to produce betulin with high sterility and immunogenicity, which improves the quality of the vaccine against the coronavirus.
    Type: Application
    Filed: August 9, 2021
    Publication date: April 11, 2024
    Inventors: Artur Alexandrovich ISAEV, Igor Viktorovich KRASILNIKOV, Maria Evgenievna FLOLOVA, Alexander Viktorovich KUDRYAVTSEV, Anna Vladimirovna VAKHRUSHEVA, Alexander Viktorovich IVANOV
  • PARAMYXOVIRUS VACCINE STRAIN FOR NOVEL CORONAVIRUS PNEUMONIA AND CONSTRUCTION METHOD THEREOF
    Publication number: 20220323571
    Abstract: A paramyxovirus vaccine strain for novel coronavirus pneumonia and a construction method thereof are provided. The method includes performing a recombination of N and F genes of Newcastle disease virus type VII of Paramyxoviridae with P, M, H, L genes of Canine distemper virus of Paramyxoviridae to obtain a recombinant virus, inserting S1 gene of the novel coronavirus between the P and M genes of the recombinant virus to obtain a recombinant vector. The vaccine strain constructed can stably and efficiently express the novel coronavirus S1 protein, and induce the body to produce antibodies; and the recombined virus vaccine strain can stimulate the human body to produce mucosal immunity, and the prepared vaccine can be vaccinated through a nasal spray. Moreover, the vaccine strain can be tested in poultry and dogs, saving time, reducing costs, and being more conducive to actual production due to large output.
    Type: Application
    Filed: August 17, 2021
    Publication date: October 13, 2022
    Inventors: MINGYI LI, GANG LIU, CHUNLIN YI, FENGLONG MA, ZONGKE WANG, YUJIE XIA, XIAOCHEN CUI, ZHEN YANG, HONGSHANG CHANG, BINGBING ZHAO, JIE YANG
  • CORONAVIRUS RNA VACCINES
    Publication number: 20230108894
    Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 6, 2023
    Applicant: Moderna TX, Inc
    Inventors: Guillaume Stewart-Jones, Elisabeth Narayanan, Hamilton Bennett, Andrea Carfi, Mihir Metkar, Vladimir Presnyak
  • NOVEL CORONAVIRUS RECOMBINANT SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING SAME, VECTOR COMPRISING POLYNUCLEOTIDE, AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION, COMPRISING VECTOR
    Publication number: 20230293670
    Abstract: The present invention relates to a novel coronavirus recombinant spike protein, a polynucleotide encoding the same, a vector comprising the polynucleotide, and a vaccine for preventing or treating coronavirus infection, comprising the vector. The coronavirus recombinant spike protein of the present invention is stable and thereby not easily decomposed in cells, and effectively activates immune cells thereby resulting in a high antibody production amount and T cell reactivity. It was confirmed that the vector of the present invention exhibits a high antigen expression level and thereby has a high antibody production amount and T cell reactivity, has a long antibody production period and expression period, and does not show liver toxicity. Accordingly, the vector of the present invention can be helpfully used as a vaccine for preventing or treating coronavirus infection.
    Type: Application
    Filed: August 27, 2021
    Publication date: September 21, 2023
    Inventors: Chang-Yuil KANG, Seung-Phil SHIN, Kwang-Soo SHIN, Tae-Gwon OH
  • Paramyxovirus vaccine strain for novel coronavirus pneumonia and construction method thereof
    Patent number: 11484588
    Abstract: A paramyxovirus vaccine strain for novel coronavirus pneumonia and a construction method thereof are provided. The method includes performing a recombination of N and F genes of Newcastle disease virus type VII of Paramyxoviridae with P, M, H, L genes of Canine distemper virus of Paramyxoviridae to obtain a recombinant virus, inserting S1 gene of the novel coronavirus between the P and M genes of the recombinant virus to obtain a recombinant vector. The vaccine strain constructed can stably and efficiently express the novel coronavirus S1 protein, and induce the body to produce antibodies; and the recombined virus vaccine strain can stimulate the human body to produce mucosal immunity, and the prepared vaccine can be vaccinated through a nasal spray. Moreover, the vaccine strain can be tested in poultry and dogs, saving time, reducing costs, and being more conducive to actual production due to large output.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: November 1, 2022
    Assignee: QINGDAO HARWARS BIOLOGY GROUP LTD.
    Inventors: Mingyi Li, Gang Liu, Chunlin Yi, Fenglong Ma, Zongke Wang, Yujie Xia, Xiaochen Cui, Zhen Yang, Hongshang Chang, Bingbing Zhao, Jie Yang
  • MERS CORONAVIRUS VACCINE
    Publication number: 20190351048
    Abstract: The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.
    Type: Application
    Filed: December 22, 2017
    Publication date: November 21, 2019
    Inventor: Susanne RAUCH
Narrow Results

Filter by US Classification